👪

Inheritance

2

Autosomal dominant HP:0000006

Heterozygous FOXE3 mutations can cause anterior segment dysgenesis with dominant inheritance. Phenotypes are highly variable, ranging from isolated congenital cataract to Peters anomaly and colobomas. Penetrance is high with variable expressivity, and genetic background influences the phenotypic outcome.

Autosomal dominant inheritance

Show evidence (2 references)

PMID:19708017 SUPPORT Human Clinical

"we report two further novel heterozygous mutations segregating in a dominant fashion in two different families"

Identifies dominant FOXE3 mutations segregating in families with variable anterior segment phenotypes.

PMID:11980846 SUPPORT Model Organism

"Haploinsufficiency of Foxe3 in a mouse model causes anterior segment dysgenesis similar to Peters' anomaly"

Mouse model demonstrates that Foxe3 haploinsufficiency recapitulates dominant anterior segment dysgenesis.

Autosomal recessive HP:0000007

Homozygous loss-of-function FOXE3 mutations cause complete failure of lens development resulting in congenital primary aphakia. This severe recessive form has been identified in multiple consanguineous families from Pakistan, Madagascar, and Mexico. Heterozygous carriers in these families are unaffected.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:16826526 SUPPORT Human Clinical

"a null mutation in the FOXE3 gene segregates and, in the homozygous state, produces the mutant phenotype in this family"

Demonstrates autosomal recessive inheritance of congenital primary aphakia caused by homozygous FOXE3 null mutation.

PMID:20361012 SUPPORT Human Clinical

"FOXE3 is responsible for the early developmental arrest of the lens placode, and the complete loss of a functional FOXE3 protein results in primary aphakia"

Confirms autosomal recessive inheritance of FOXE3-related primary aphakia in an independent family.

◆

Subtypes

2

Congenital Cataract (Dominant, Partial LOF)

Autosomal dominant form caused by heterozygous FOXE3 mutations resulting in partial loss of function or haploinsufficiency. Phenotypes are highly variable and include congenital cataract (cerulean type and early onset nuclear/cortical cataract), Peters anomaly, iris colobomas, and other anterior segment defects. Penetrance is high with variable expressivity.

Show evidence (2 references)

PMID:19708017 SUPPORT Human Clinical

"the dominant mutations were penetrant, they gave rise to highly variable phenotypes including iris and chorioretinal colobomas, Peters' anomaly, and isolated cataract (cerulean type and early onset adult nuclear and cortical cataract)"

Describes the variable phenotypic spectrum of dominant FOXE3 mutations including cataracts and anterior segment anomalies.

PMID:20806047 SUPPORT Human Clinical

"A novel dominant mutation at the stop codon of FOXE3, c.959G>C (p.X320SerextX72), was identified in a patient with congenital cataract"

Identifies a dominant non-stop FOXE3 mutation causing congenital cataract.

Primary Aphakia (Recessive, Complete LOF)

Autosomal recessive form caused by homozygous null FOXE3 mutations leading to complete loss of function. Characterized by bilateral congenital absence of the lens (aphakia) with secondary aplasia of the anterior segment, sclerocornea, microphthalmia, and in some cases optic disc coloboma. Results from early developmental arrest of the lens placode around the 4th-5th week of embryogenesis.

Show evidence (2 references)

PMID:16826526 SUPPORT Human Clinical

"Congenital primary aphakia (CPA) is a rare developmental disorder characterized by the absence of lens, the development of which is normally induced during the 4th-5th wk of human embryogenesis"

First identification of FOXE3 as the causative gene for congenital primary aphakia in humans.

PMID:20664696 SUPPORT Human Clinical

"MRI or ultrasonography confirmed that the patients with sclerocornea were also aphakic, had microphthalmia and some had optic disc coloboma"

Confirms the full recessive phenotype including sclerocornea, aphakia, microphthalmia, and optic disc coloboma.

⚙

Pathophysiology

2

Failed Lens Placode Induction and Differentiation

FOXE3 is a forkhead transcription factor expressed exclusively in the anterior lens epithelium. It is a downstream target of PAX6 and RX and acts as one of the earliest integrators of FGF, BMP, and WNT signaling pathways that cooperate to induce lens formation. In homozygous loss-of-function mutations, complete absence of FOXE3 activity prevents lens placode development during the 4th-5th week of embryogenesis, resulting in primary aphakia. Because the lens serves as an organizer for anterior segment morphogenesis, its absence leads to secondary aplasia of iris, cornea, and anterior chamber structures.

Lens epithelial cell link

FOXE3 link

Lens development link Lens fiber cell differentiation link

DNA-binding transcription factor activity, RNA polymerase II-specific link

Downstream

Secondary Anterior Segment Aplasia Absence of the lens leads to secondary malformation of the anterior segment structures.

Show evidence (3 references)

PMID:10890982 SUPPORT Model Organism

"During development Foxe3 is expressed in all undifferentiated lens tissues, and is turned off upon fiber cell differentiation"

Establishes Foxe3 as a lens-specific developmental transcription factor required for proper lens formation.

PMID:17344231 SUPPORT Other

"Foxe3 had been shown to play a crucial role in vertebrate lens formation and this gene is one of the earliest integrators of several signaling pathways that cooperate to form a lens"

Reviews the central role of FOXE3 in integrating lens developmental signaling pathways.

PMID:16826526 SUPPORT Human Clinical

"it indicates a possible critical role for FOXE3 very early in the lens developmental program, perhaps earlier than any role recognized elsewhere for this gene"

Suggests FOXE3 plays a very early role in lens development, consistent with aphakia as the null phenotype.

Secondary Anterior Segment Aplasia

The lens acts as a critical organizer for anterior segment morphogenesis. In the absence of a lens (aphakia) or with abnormal lens development, secondary malformation of the iris, cornea, and anterior chamber occurs. This explains why FOXE3 mutations, despite the gene being expressed only in the lens, produce extralenticular phenotypes including sclerocornea, Peters anomaly, and iris colobomas.

Camera-type eye morphogenesis link

Show evidence (2 references)

PMID:19708017 SUPPORT Human Clinical

"expression of FOXE3 restricted to lens tissue, predominantly in the anterior epithelium, suggesting that the extralenticular phenotypes caused by FOXE3 mutations are most likely to be secondary to abnormal lens formation"

Demonstrates that extralenticular phenotypes are secondary to primary lens defects, since FOXE3 expression is restricted to the lens.

PMID:11980846 SUPPORT Model Organism

"Approximately 40% of mice heterozygous for Foxe3(dyl) have corneal and lenticular defects"

Mouse haploinsufficiency model shows secondary corneal defects arising from primary lens abnormalities.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Congenital Cataract Clinical HP:0000519

Show evidence (1 reference)

PMID:19708017 SUPPORT Human Clinical

"isolated cataract (cerulean type and early onset adult nuclear and cortical cataract)"

Documents cataract subtypes observed with dominant FOXE3 mutations.

Congenital Aphakia Clinical HP:0007707

Show evidence (1 reference)

PMID:16826526 SUPPORT Human Clinical

"Congenital primary aphakia (CPA) is a rare developmental disorder characterized by the absence of lens"

Defines congenital primary aphakia as the hallmark phenotype of homozygous FOXE3 loss.

Microphthalmia Clinical HP:0000568

Show evidence (1 reference)

PMID:19708017 SUPPORT Human Clinical

"we identify new recessive FOXE3 mutations causative for microphthalmia, sclerocornea, primary aphakia, and glaucoma"

Microphthalmia is a consistent feature of recessive FOXE3 disease.

Sclerocornea Clinical HP:0000647

Show evidence (1 reference)

PMID:20664696 SUPPORT Human Clinical

"Previous papers have emphasized aphakia and microphthalmia as the primary phenotype, but we find that the initial diagnosis - and perhaps the only one possible in a rural setting - is one of non-syndromic, bilateral, total sclerocornea"

Highlights sclerocornea as a prominent presenting feature of homozygous FOXE3 mutations.

Peters Anomaly Clinical HP:0000659

Show evidence (2 references)

PMID:11980846 SUPPORT Model Organism

"The phenotype is variable but typically consists of the equivalent of Peters' anomaly in humans, with central corneal opacity, keratolenticular adhesion, and, in some cases, anterior polar cataract"

Mouse model of Foxe3 haploinsufficiency demonstrates Peters anomaly phenotype.

PMID:19708017 SUPPORT Human Clinical

"the dominant mutations were penetrant, they gave rise to highly variable phenotypes including iris and chorioretinal colobomas, Peters' anomaly, and isolated cataract"

Documents Peters anomaly in human patients with heterozygous FOXE3 mutations.

Ocular Anterior Segment Dysgenesis Clinical HP:0007700

Show evidence (1 reference)

PMID:16826526 SUPPORT Human Clinical

"This original failure leads, in turn, to complete aplasia of the anterior segment of the eye, which is the diagnostic histological criterion for CPA"

Anterior segment aplasia is the secondary consequence of primary lens failure in FOXE3 disease.

Glaucoma Clinical HP:0000501

Show evidence (1 reference)

PMID:19708017 SUPPORT Human Clinical

"recessive FOXE3 mutations causative for microphthalmia, sclerocornea, primary aphakia, and glaucoma"

Glaucoma is part of the recessive FOXE3 phenotypic spectrum.

🧬

Genetic Associations

1

FOXE3 (Causative)

Show evidence (3 references)

PMID:10890982 SUPPORT Model Organism

"During development Foxe3 is expressed in all undifferentiated lens tissues, and is turned off upon fiber cell differentiation"

Original discovery that Foxe3 maps to the dysgenetic lens locus and is critical for lens development.

PMID:17344231 SUPPORT Other

"Foxe3 had been shown to play a crucial role in vertebrate lens formation and this gene is one of the earliest integrators of several signaling pathways that cooperate to form a lens"

Review confirming FOXE3 as a central integrator of lens developmental signaling.

CGGV:assertion_c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3-2025-04-15T160000.000Z SUPPORT Other

ClinGen classifies the FOXE3-anterior segment dysgenesis gene-disease relationship as moderate with undetermined inheritance.

{ }

Source YAML

click to show

name: FOXE3-Related Anterior Segment Dysgenesis
creation_date: "2026-04-04T00:00:00Z"
updated_date: "2026-04-07T02:14:34Z"
category: Mendelian
description: >
  FOXE3-related anterior segment dysgenesis is a spectrum of developmental eye
  disorders caused by mutations in FOXE3, encoding a forkhead transcription factor
  specifically expressed in the lens epithelium. FOXE3 is one of the earliest
  integrators of signaling pathways that cooperate to form the lens during
  embryogenesis. The clinical spectrum ranges from mild anterior segment anomalies
  and congenital cataract (autosomal dominant, partial loss of function) to severe
  congenital primary aphakia with sclerocornea and microphthalmia (autosomal
  recessive, complete loss of function). Heterozygous mutations produce variable
  phenotypes including Peters anomaly, cerulean cataract, and colobomas, while
  homozygous null mutations cause complete failure of lens development with
  secondary aplasia of the anterior segment.
disease_term:
  preferred_term: FOXE3-related anterior segment dysgenesis
  term:
    id: MONDO:0019503
    label: anterior segment dysgenesis
parents:
- Eye Disorders
has_subtypes:
- name: Congenital Cataract
  display_name: Congenital Cataract (Dominant, Partial LOF)
  description: >
    Autosomal dominant form caused by heterozygous FOXE3 mutations resulting in
    partial loss of function or haploinsufficiency. Phenotypes are highly variable
    and include congenital cataract (cerulean type and early onset nuclear/cortical
    cataract), Peters anomaly, iris colobomas, and other anterior segment defects.
    Penetrance is high with variable expressivity.
  evidence:
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the dominant mutations were penetrant, they gave rise to highly variable phenotypes including iris and chorioretinal colobomas, Peters' anomaly, and isolated cataract (cerulean type and early onset adult nuclear and cortical cataract)"
    explanation: "Describes the variable phenotypic spectrum of dominant FOXE3 mutations including cataracts and anterior segment anomalies."
  - reference: PMID:20806047
    reference_title: "Identification of dominant FOXE3 and PAX6 mutations in patients with congenital cataract and aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel dominant mutation at the stop codon of FOXE3, c.959G>C (p.X320SerextX72), was identified in a patient with congenital cataract"
    explanation: "Identifies a dominant non-stop FOXE3 mutation causing congenital cataract."
- name: Primary Aphakia
  display_name: Primary Aphakia (Recessive, Complete LOF)
  description: >
    Autosomal recessive form caused by homozygous null FOXE3 mutations leading to
    complete loss of function. Characterized by bilateral congenital absence of
    the lens (aphakia) with secondary aplasia of the anterior segment, sclerocornea,
    microphthalmia, and in some cases optic disc coloboma. Results from early
    developmental arrest of the lens placode around the 4th-5th week of embryogenesis.
  evidence:
  - reference: PMID:16826526
    reference_title: "Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Congenital primary aphakia (CPA) is a rare developmental disorder characterized by the absence of lens, the development of which is normally induced during the 4th-5th wk of human embryogenesis"
    explanation: "First identification of FOXE3 as the causative gene for congenital primary aphakia in humans."
  - reference: PMID:20664696
    reference_title: "Homozygous FOXE3 mutations cause non-syndromic, bilateral, total sclerocornea, aphakia, microphthalmia and optic disc coloboma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI or ultrasonography confirmed that the patients with sclerocornea were also aphakic, had microphthalmia and some had optic disc coloboma"
    explanation: "Confirms the full recessive phenotype including sclerocornea, aphakia, microphthalmia, and optic disc coloboma."
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    Heterozygous FOXE3 mutations can cause anterior segment dysgenesis with
    dominant inheritance. Phenotypes are highly variable, ranging from isolated
    congenital cataract to Peters anomaly and colobomas. Penetrance is high
    with variable expressivity, and genetic background influences the phenotypic outcome.
  evidence:
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we report two further novel heterozygous mutations segregating in a dominant fashion in two different families"
    explanation: "Identifies dominant FOXE3 mutations segregating in families with variable anterior segment phenotypes."
  - reference: PMID:11980846
    reference_title: "Foxe3 haploinsufficiency in mice: a model for Peters' anomaly."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Haploinsufficiency of Foxe3 in a mouse model causes anterior segment dysgenesis similar to Peters' anomaly"
    explanation: "Mouse model demonstrates that Foxe3 haploinsufficiency recapitulates dominant anterior segment dysgenesis."
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Homozygous loss-of-function FOXE3 mutations cause complete failure of lens
    development resulting in congenital primary aphakia. This severe recessive form
    has been identified in multiple consanguineous families from Pakistan, Madagascar,
    and Mexico. Heterozygous carriers in these families are unaffected.
  evidence:
  - reference: PMID:16826526
    reference_title: "Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a null mutation in the FOXE3 gene segregates and, in the homozygous state, produces the mutant phenotype in this family"
    explanation: "Demonstrates autosomal recessive inheritance of congenital primary aphakia caused by homozygous FOXE3 null mutation."
  - reference: PMID:20361012
    reference_title: "A mutation in the FOXE3 gene causes congenital primary aphakia in an autosomal recessive consanguineous Pakistani family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FOXE3 is responsible for the early developmental arrest of the lens placode, and the complete loss of a functional FOXE3 protein results in primary aphakia"
    explanation: "Confirms autosomal recessive inheritance of FOXE3-related primary aphakia in an independent family."
genetic:
- name: FOXE3
  features: Forkhead transcription factor essential for lens development; mutations range from partial to complete loss of function
  gene_term:
    preferred_term: FOXE3
    term:
      id: hgnc:3808
      label: FOXE3
  association: Causative
  notes: >
    FOXE3 encodes a forkhead domain transcription factor expressed exclusively in
    the lens anterior epithelium during eye development. It is a critical downstream
    target of PAX6 and RX, and one of the earliest integrators of signaling pathways
    required for lens formation. Dominant mutations (heterozygous, often non-stop or
    missense in the forkhead domain) produce partial loss of function with variable
    anterior segment anomalies. Recessive mutations (homozygous nonsense or
    loss-of-function missense) produce complete loss of function with aphakia.
  evidence:
  - reference: PMID:10890982
    reference_title: "Forkhead Foxe3 maps to the dysgenetic lens locus and is critical in lens development and differentiation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "During development Foxe3 is expressed in all undifferentiated lens tissues, and is turned off upon fiber cell differentiation"
    explanation: "Original discovery that Foxe3 maps to the dysgenetic lens locus and is critical for lens development."
  - reference: PMID:17344231
    reference_title: "Foxe view of lens development and disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Foxe3 had been shown to play a crucial role in vertebrate lens formation and this gene is one of the earliest integrators of several signaling pathways that cooperate to form a lens"
    explanation: "Review confirming FOXE3 as a central integrator of lens developmental signaling."
  - reference: CGGV:assertion_c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3-2025-04-15T160000.000Z
    reference_title: "FOXE3 / anterior segment dysgenesis (Moderate)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FOXE3 | HGNC:3808 | anterior segment dysgenesis | MONDO:0019503 | UD | Moderate"
    explanation: ClinGen classifies the FOXE3-anterior segment dysgenesis gene-disease relationship as moderate with undetermined inheritance.
phenotypes:
- name: Congenital Cataract
  category: Clinical
  subtype: Congenital Cataract
  description: >
    Lens opacification present at birth or early childhood. In dominant FOXE3
    mutations, cataracts can be cerulean type, nuclear, or cortical.
  phenotype_term:
    preferred_term: Congenital cataract
    term:
      id: HP:0000519
      label: Developmental cataract
  evidence:
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "isolated cataract (cerulean type and early onset adult nuclear and cortical cataract)"
    explanation: "Documents cataract subtypes observed with dominant FOXE3 mutations."
- name: Congenital Aphakia
  category: Clinical
  subtype: Primary Aphakia
  description: >
    Complete absence of the lens due to failure of lens placode development
    during the 4th-5th week of embryogenesis. Pathognomonic feature of recessive
    FOXE3 mutations.
  phenotype_term:
    preferred_term: Congenital aphakia
    term:
      id: HP:0007707
      label: Congenital aphakia
  evidence:
  - reference: PMID:16826526
    reference_title: "Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Congenital primary aphakia (CPA) is a rare developmental disorder characterized by the absence of lens"
    explanation: "Defines congenital primary aphakia as the hallmark phenotype of homozygous FOXE3 loss."
- name: Microphthalmia
  category: Clinical
  subtype: Primary Aphakia
  description: >
    Abnormally small eyes, typically bilateral, observed in patients with
    homozygous FOXE3 mutations as a secondary consequence of failed lens
    induction.
  phenotype_term:
    preferred_term: Microphthalmia
    term:
      id: HP:0000568
      label: Microphthalmia
  evidence:
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identify new recessive FOXE3 mutations causative for microphthalmia, sclerocornea, primary aphakia, and glaucoma"
    explanation: "Microphthalmia is a consistent feature of recessive FOXE3 disease."
- name: Sclerocornea
  category: Clinical
  subtype: Primary Aphakia
  description: >
    Non-inflammatory opacification of the cornea in which the cornea resembles
    scleral tissue. Total bilateral sclerocornea is a prominent feature of
    recessive FOXE3 mutations.
  phenotype_term:
    preferred_term: Sclerocornea
    term:
      id: HP:0000647
      label: Sclerocornea
  evidence:
  - reference: PMID:20664696
    reference_title: "Homozygous FOXE3 mutations cause non-syndromic, bilateral, total sclerocornea, aphakia, microphthalmia and optic disc coloboma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Previous papers have emphasized aphakia and microphthalmia as the primary phenotype, but we find that the initial diagnosis - and perhaps the only one possible in a rural setting - is one of non-syndromic, bilateral, total sclerocornea"
    explanation: "Highlights sclerocornea as a prominent presenting feature of homozygous FOXE3 mutations."
- name: Peters Anomaly
  category: Clinical
  subtype: Congenital Cataract
  description: >
    Central corneal opacity with iridocorneal or keratolenticular adhesions.
    Associated with heterozygous FOXE3 mutations (dominant) and represents
    incomplete anterior segment dysgenesis.
  phenotype_term:
    preferred_term: Peters anomaly
    term:
      id: HP:0000659
      label: Peters anomaly
  evidence:
  - reference: PMID:11980846
    reference_title: "Foxe3 haploinsufficiency in mice: a model for Peters' anomaly."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The phenotype is variable but typically consists of the equivalent of Peters' anomaly in humans, with central corneal opacity, keratolenticular adhesion, and, in some cases, anterior polar cataract"
    explanation: "Mouse model of Foxe3 haploinsufficiency demonstrates Peters anomaly phenotype."
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the dominant mutations were penetrant, they gave rise to highly variable phenotypes including iris and chorioretinal colobomas, Peters' anomaly, and isolated cataract"
    explanation: "Documents Peters anomaly in human patients with heterozygous FOXE3 mutations."
- name: Ocular Anterior Segment Dysgenesis
  category: Clinical
  description: >
    Broad developmental abnormality of the anterior segment of the eye, which
    can include iris anomalies, corneal opacities, and lens defects. Represents
    the overarching phenotypic category.
  phenotype_term:
    preferred_term: Ocular anterior segment dysgenesis
    term:
      id: HP:0007700
      label: Ocular anterior segment dysgenesis
  evidence:
  - reference: PMID:16826526
    reference_title: "Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This original failure leads, in turn, to complete aplasia of the anterior segment of the eye, which is the diagnostic histological criterion for CPA"
    explanation: "Anterior segment aplasia is the secondary consequence of primary lens failure in FOXE3 disease."
- name: Glaucoma
  category: Clinical
  subtype: Primary Aphakia
  description: >
    Elevated intraocular pressure and optic nerve damage, observed as a
    secondary consequence of anterior segment maldevelopment in recessive
    FOXE3 disease.
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "recessive FOXE3 mutations causative for microphthalmia, sclerocornea, primary aphakia, and glaucoma"
    explanation: "Glaucoma is part of the recessive FOXE3 phenotypic spectrum."
pathophysiology:
- name: Failed Lens Placode Induction and Differentiation
  description: >
    FOXE3 is a forkhead transcription factor expressed exclusively in the anterior
    lens epithelium. It is a downstream target of PAX6 and RX and acts as one of
    the earliest integrators of FGF, BMP, and WNT signaling pathways that
    cooperate to induce lens formation. In homozygous loss-of-function mutations,
    complete absence of FOXE3 activity prevents lens placode development during
    the 4th-5th week of embryogenesis, resulting in primary aphakia. Because the
    lens serves as an organizer for anterior segment morphogenesis, its absence
    leads to secondary aplasia of iris, cornea, and anterior chamber structures.
  genes:
  - preferred_term: FOXE3
    term:
      id: hgnc:3808
      label: FOXE3
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity, RNA polymerase II-specific
    term:
      id: GO:0000981
      label: DNA-binding transcription factor activity, RNA polymerase II-specific
  cell_types:
  - preferred_term: Lens epithelial cell
    term:
      id: CL:0002224
      label: lens epithelial cell
  biological_processes:
  - preferred_term: Lens development
    term:
      id: GO:0002088
      label: lens development in camera-type eye
  - preferred_term: Lens fiber cell differentiation
    term:
      id: GO:0070306
      label: lens fiber cell differentiation
  evidence:
  - reference: PMID:10890982
    reference_title: "Forkhead Foxe3 maps to the dysgenetic lens locus and is critical in lens development and differentiation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "During development Foxe3 is expressed in all undifferentiated lens tissues, and is turned off upon fiber cell differentiation"
    explanation: "Establishes Foxe3 as a lens-specific developmental transcription factor required for proper lens formation."
  - reference: PMID:17344231
    reference_title: "Foxe view of lens development and disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Foxe3 had been shown to play a crucial role in vertebrate lens formation and this gene is one of the earliest integrators of several signaling pathways that cooperate to form a lens"
    explanation: "Reviews the central role of FOXE3 in integrating lens developmental signaling pathways."
  - reference: PMID:16826526
    reference_title: "Homozygous nonsense mutation in the FOXE3 gene as a cause of congenital primary aphakia in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it indicates a possible critical role for FOXE3 very early in the lens developmental program, perhaps earlier than any role recognized elsewhere for this gene"
    explanation: "Suggests FOXE3 plays a very early role in lens development, consistent with aphakia as the null phenotype."
  downstream:
  - target: Secondary Anterior Segment Aplasia
    description: Absence of the lens leads to secondary malformation of the anterior segment structures.
- name: Secondary Anterior Segment Aplasia
  description: >
    The lens acts as a critical organizer for anterior segment morphogenesis. In
    the absence of a lens (aphakia) or with abnormal lens development, secondary
    malformation of the iris, cornea, and anterior chamber occurs. This explains
    why FOXE3 mutations, despite the gene being expressed only in the lens, produce
    extralenticular phenotypes including sclerocornea, Peters anomaly, and iris
    colobomas.
  biological_processes:
  - preferred_term: Camera-type eye morphogenesis
    term:
      id: GO:0048593
      label: camera-type eye morphogenesis
  evidence:
  - reference: PMID:19708017
    reference_title: "Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "expression of FOXE3 restricted to lens tissue, predominantly in the anterior epithelium, suggesting that the extralenticular phenotypes caused by FOXE3 mutations are most likely to be secondary to abnormal lens formation"
    explanation: "Demonstrates that extralenticular phenotypes are secondary to primary lens defects, since FOXE3 expression is restricted to the lens."
  - reference: PMID:11980846
    reference_title: "Foxe3 haploinsufficiency in mice: a model for Peters' anomaly."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Approximately 40% of mice heterozygous for Foxe3(dyl) have corneal and lenticular defects"
    explanation: "Mouse haploinsufficiency model shows secondary corneal defects arising from primary lens abnormalities."
animal_models:
- species: Mouse
  genotype: Foxe3(dyl/dyl) (dysgenetic lens)
  description: >
    Homozygous dysgenetic lens (dyl) mice carry a loss-of-function mutation in
    Foxe3 and display severe lens developmental defects including failure of lens
    vesicle closure, dysregulated crystallin expression, and anterior segment
    anomalies. The dyl allele encodes a protein unable to bind DNA.
  evidence:
  - reference: PMID:10890982
    reference_title: "Forkhead Foxe3 maps to the dysgenetic lens locus and is critical in lens development and differentiation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mice homozygous for dyl display several defects in lens development. dyl mice also show altered patterns of crystallin expression suggesting a dysregulation of lens differentiation"
    explanation: "Original mapping of Foxe3 to the dyl locus with characterization of the homozygous phenotype."
- species: Mouse
  genotype: Foxe3(dyl/+) (heterozygous)
  description: >
    Heterozygous Foxe3(dyl/+) mice model dominant anterior segment dysgenesis.
    Approximately 40% display corneal and lenticular defects equivalent to Peters
    anomaly in humans, demonstrating haploinsufficiency.
  evidence:
  - reference: PMID:11980846
    reference_title: "Foxe3 haploinsufficiency in mice: a model for Peters' anomaly."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Approximately 40% of mice heterozygous for Foxe3(dyl) have corneal and lenticular defects. The phenotype is variable but typically consists of the equivalent of Peters' anomaly in humans"
    explanation: "Demonstrates Foxe3 haploinsufficiency as a model for dominant anterior segment dysgenesis."

📚

References & Deep Research

Deep Research

1

Falcon ▸

FOXE3-Related Anterior Segment Dysgenesis (ASD2; OMIM 610256): Comprehensive Research Report

Edison Scientific Literature 28 citations 2026-04-04T12:55:23.400926

FOXE3-Related Anterior Segment Dysgenesis (ASD2; OMIM 610256): Comprehensive Research Report

Executive summary

FOXE3-related anterior segment dysgenesis is a Mendelian developmental eye disorder caused by pathogenic variants in the lens transcription factor FOXE3 (gene MIM 601094) and classically mapped to Anterior segment dysgenesis 2 (ASD2; OMIM 610256). It shows both autosomal recessive (biallelic) and autosomal dominant inheritance, with a strong genotype–phenotype relationship: biallelic loss-of-function/forkhead-domain missense variants tend to cause severe congenital malformations (corneal opacity/sclerocornea, aphakia, microphthalmia), while dominant C-terminal extension (stop-loss/non-stop) variants more often cause cataract with variable, usually milder anterior segment anomalies. (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13, iseri2009seeingclearlythe pages 2-3)

Recent (2023–2024) literature emphasizes (i) increasing availability—but high heterogeneity—of commercial gene panels for anterior segment phenotypes, (ii) the role of WES in resolving phenotypically overlapping congenital ocular disorders, and (iii) improved evidence synthesis on management and outcomes for key overlapping clinical entities (notably Peters anomaly) that frequently appear in the FOXE3 spectrum. (wowra2024generaltreatmentand pages 1-2, procopio2023comparinggenepanels pages 1-2, zucco2024abird’seye pages 3-4)

1. Disease information

1.1 Definition / overview

Anterior segment dysgenesis (ASD) comprises developmental abnormalities of the cornea, iris, lens, and iridocorneal angle. FOXE3-related ASD is a genetically defined subset in which abnormal lens development secondarily disrupts anterior segment morphogenesis, producing a spectrum from isolated cataract to severe congenital malformations such as sclerocornea–microphthalmia–aphakia complex and/or Peters anomaly. FOXE3 expression is lens-restricted, supporting a lens-primary mechanism for many downstream anterior segment findings. (iseri2009seeingclearlythe pages 1-2, iseri2009seeingclearlythe pages 2-3)

1.2 Key identifiers

Disease OMIM: 610256 (anterior segment dysgenesis 2 / congenital primary aphakia locus referenced under MIM#610256 in FOXE3 literature). (iseri2009seeingclearlythe pages 2-3, reis2021comprehensivephenotypicand pages 2-2)
Causal gene OMIM: FOXE3 MIM 601094. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, iseri2009seeingclearlythe pages 2-3)
Genomic locus: 1p33 for FOXE3. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, iseri2009seeingclearlythe pages 2-3)
MONDO / Orphanet / ICD / MeSH: Not explicitly provided in the retrieved full texts; these should be added via direct lookup in OMIM/Orphanet/MONDO/NCBI MeSH during curation. (iseri2009seeingclearlythe pages 2-3, reis2021comprehensivephenotypicand pages 14-14)

1.3 Common synonyms / alternative names

Because FOXE3 variants yield multiple overlapping clinical diagnoses, the phenotype is often reported under: * Anterior segment dysgenesis (ASD) * Peters anomaly (when central corneal opacity with irido-/lenticulo-corneal adhesions is present) (doucette2011anovelnonstop pages 1-2, wowra2024generaltreatmentand pages 1-2) * Congenital primary aphakia (when lens is absent congenitally) (iseri2009seeingclearlythe pages 2-3) * Sclerocornea–microphthalmia–aphakia complex (a severe biallelic FOXE3 phenotype) (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

1.4 Evidence source type

Most FOXE3 disease knowledge comes from aggregated disease-level resources and case series (families/case reports with sequencing) plus functional assays in cell systems, and supporting developmental biology evidence from animal models (e.g., Foxe3/dyl mouse). (semina2001mutationsinthe pages 1-2, reis2021comprehensivephenotypicand pages 1-2)

2. Etiology

2.1 Primary causal factors

Genetic (monogenic) etiology: pathogenic germline variants in FOXE3, encoding a forkhead transcription factor critical for lens development. (reis2021comprehensivephenotypicand pages 1-2, iseri2009seeingclearlythe pages 2-3)

2.2 Risk factors

Family history of congenital cataract/anterior segment anomalies consistent with AD inheritance for C-terminal extension alleles, or AR inheritance in consanguineous pedigrees. (doucette2011anovelnonstop pages 1-2, iseri2009seeingclearlythe pages 2-3)
Consanguinity increases risk for biallelic FOXE3 disease, illustrated by case-based reports and linkage approaches in consanguineous families. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, iseri2009seeingclearlythe pages 2-3)

2.3 Protective factors / gene–environment interactions

No validated protective environmental factors or gene–environment interactions were identified in the retrieved texts for FOXE3-specific disease; most evidence supports a primarily genetic developmental mechanism. (reis2021comprehensivephenotypicand pages 1-2, iseri2009seeingclearlythe pages 2-3)

3. Phenotypes

3.1 Core phenotype spectrum and frequencies (human)

The best quantitative synthesis in the retrieved evidence is from Reis et al. 2021, which explicitly stratifies recessive vs dominant FOXE3 disease: * Recessive/biallelic FOXE3: severe congenital phenotypes with corneal opacity (90%), sclerocornea (47%), aphakia (83%), microphthalmia (80%); when assessed, aniridia/iris hypoplasia (89%) and optic nerve anomalies (60%) were frequent. (reis2021comprehensivephenotypicand pages 1-2) * Dominant FOXE3 (often extension alleles): usually normal eye size (96%), cataracts (99%), and variable anterior segment anomalies with overlap in some individuals (microphthalmia/aphakia/sclerocornea can occur). (reis2021comprehensivephenotypicand pages 1-2)

Figure-based visual evidence for these phenotype distributions is provided in Figure 3 (Reis 2021). (reis2021comprehensivephenotypicand media 2b34c269, reis2021comprehensivephenotypicand media cd18957d)

Additional genotype-phenotype synthesis across the literature: * Recessive cases predominate in published FOXE3 cohorts (reported 84% recessive vs 16% dominant), with severe ocular disease much more frequent in recessive than dominant cases (77% vs 5%), and severity associated with truncating vs missense allele classes. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

3.2 Phenotype characteristics (typical)

Onset: Congenital/early childhood (developmental malformation present at birth; cataract may be congenital or progress/manifest later depending on allele class). (reis2021comprehensivephenotypicand pages 1-2, iseri2009seeingclearlythe pages 2-3)

Progression: Structural anomalies are generally non-progressive, but vision-threatening sequelae (e.g., amblyopia, glaucoma, corneal graft outcomes) can evolve over time. (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 4-7)

3.3 Suggested HPO terms (examples)

(ontology suggestions; confirm exact mappings during curation) * Anterior segment dysgenesis — HP:0000649 * Peters anomaly — HP:0000570 * Corneal opacity — HP:0007957 * Sclerocornea — HP:0000678 * Microphthalmia — HP:0000568 * Aphakia — HP:0000565 * Cataract — HP:0000518 * Glaucoma — HP:0000501 * Iris hypoplasia / aniridia — HP:0000528 / HP:0000526 * Optic nerve hypoplasia/anomaly — HP:0000609

3.4 Quality of life impact

Although FOXE3-specific quality-of-life instrument data were not found in the retrieved texts, the phenotype spectrum includes high-impact outcomes (childhood visual impairment/blindness, multiple surgeries, long-term amblyopia therapy and glaucoma monitoring). For Peters anomaly (a frequent overlapping entity), half of infants/children may achieve “functional vision” after surgical treatment in some series, but severe outcomes including no light perception are also reported. (wowra2024generaltreatmentand pages 7-8, wowra2024generaltreatmentand pages 4-7)

4. Genetic / molecular information

4.1 Causal gene

Gene: FOXE3 (forkhead box E3), MIM 601094, located at 1p33. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, iseri2009seeingclearlythe pages 2-3)

4.2 Pathogenic variant classes and functional consequences

A major current understanding is that variant class correlates with inheritance mode and severity: * Biallelic recessive disease: often truncating (frameshift/nonsense) or forkhead-domain missense variants consistent with reduced FOXE3 function; functional assays show variable impacts on stability/DNA binding/nuclear localization/transcriptional activity depending on substitution/position. (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13) * Dominant disease: commonly C-terminal extension/stop-loss (“elongating/non-stop”) variants; Reis et al. report dominant-negative characteristics in functional studies of dominant alleles. (reis2021comprehensivephenotypicand pages 1-2, doucette2011anovelnonstop pages 1-2)

Concrete variant-class examples documented in the literature include missense, truncating frameshift, and stop-loss/extension variants (e.g., FOXE3 p.X320ArgextX72 and related stop-codon disruptions). (iseri2009seeingclearlythe pages 2-3)

4.3 Genotype–phenotype correlations (quantitative)

Plaisancié et al. 2018 provides cross-study quantitative synthesis: * With ≥1 truncating allele: 90% (37/41) severe ocular phenotype. * With biallelic missense alleles: 69% (42/61) severe ocular disease. * ASD more frequent with two missense alleles (31%; 19/61) than with two truncating alleles (17%; 4/23). (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No FOXE3-specific modifier-gene or epigenetic disease mechanism evidence was identified in the retrieved texts.

5. Environmental information

No validated environmental contributors are established for FOXE3-related ASD2 in the retrieved evidence; disease is principally genetic and developmental. (reis2021comprehensivephenotypicand pages 1-2)

6. Mechanism / pathophysiology

6.1 Current mechanistic model (causal chain)

Upstream: germline pathogenic variant in FOXE3, a lens transcription factor with forkhead DNA-binding domain. (iseri2009seeingclearlythe pages 2-3)

Intermediate: disrupted lens development/maintenance, leading to abnormal lens epithelium behavior and lens morphogenesis; dominant and recessive alleles differ mechanistically (dominant-negative vs loss-of-function spectrum). (reis2021comprehensivephenotypicand pages 1-2)

Downstream: secondary abnormal development of adjacent anterior segment structures (cornea, iris, iridocorneal angle), producing phenotypes such as corneal opacity/sclerocornea, adhesions characteristic of Peters anomaly, and angle abnormalities predisposing to glaucoma. (doucette2011anovelnonstop pages 1-2, wowra2024generaltreatmentand pages 1-2)

6.2 Suggested GO biological process terms (examples)

(ontology suggestions; confirm during curation) * Eye development — GO:0001654 * Lens development in camera-type eye — GO:0002088 * Anterior/posterior pattern specification (eye) — related developmental GO terms * Regulation of transcription by RNA polymerase II — GO:0006357 (FOXE3 as transcription factor)

6.3 Suggested cell types (CL) and anatomical sites (UBERON)

(ontology suggestions; confirm during curation) * Lens epithelial cell (CL term; lens anterior epithelium implicated) (iseri2009seeingclearlythe pages 1-2) * UBERON structures: lens (UBERON:0000965), cornea (UBERON:0000964), iris (UBERON:0001769), anterior chamber angle / trabecular meshwork / Schlemm canal (angle structures relevant to glaucoma risk). (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 2-4)

7. Anatomical structures affected

Primary organ: eye.

Primary structures: lens (aphakia/cataract), cornea (opacity/sclerocornea), iris (hypoplasia/aniridia, adhesions), iridocorneal angle (glaucoma risk), optic nerve (anomalies in a subset). (reis2021comprehensivephenotypicand pages 1-2)

Laterality: can be bilateral or unilateral depending on allele and phenotype; microphthalmia and Peters anomaly can be unilateral or bilateral in broader ASD cohorts. (reis2021comprehensivephenotypicand pages 2-2, wowra2024generaltreatmentand pages 2-4)

8. Temporal development

Onset: congenital (developmental malformation). (reis2021comprehensivephenotypicand pages 1-2)

Course: lifelong structural ocular phenotype; clinical course largely defined by visual axis clarity, amblyopia risk, and management of complications such as glaucoma and corneal graft failure (when present). (wowra2024generaltreatmentand pages 7-8, wowra2024generaltreatmentand pages 4-7)

9. Inheritance and population

9.1 Inheritance pattern

Autosomal recessive (biallelic) FOXE3 disease: typically severe congenital malformations; heterozygous carriers often unaffected. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13, reis2021comprehensivephenotypicand pages 2-2)
Autosomal dominant FOXE3 disease: typically cataract with variable ASD features; can show variable expressivity across family members. (doucette2011anovelnonstop pages 1-2, iseri2009seeingclearlythe pages 2-3)

9.2 Epidemiology

Direct prevalence/incidence of FOXE3-ASD2 is not provided in the retrieved texts.

However, broader context: * Developmental eye anomalies collectively have been cited as an important contributor to childhood visual impairment, and anophthalmia/microphthalmia has been reported around 0.6–3.2 per 10,000 in aggregated reviews, with FOXE3 accounting for a small fraction of such cases in some series. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4)

10. Diagnostics

10.1 Clinical evaluation

Common diagnostic components across FOXE3 and related ASD phenotypes include slit-lamp exam, tonometry, gonioscopy, corneal diameter measurement, and ocular biometry/ultrasound; in severe corneal opacity, exam under anesthesia is often needed. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, doucette2011anovelnonstop pages 1-2)

10.2 Imaging and ancillary testing

For Peters anomaly (often in the FOXE3 spectrum), 2024 guidance emphasizes: * Anterior-segment OCT (AS-OCT) and ultrasound biomicroscopy (UBM) * A/B-scan ultrasound when posterior pathology is suspected * Gonioscopy and (in some cases) electrophysiology to assess posterior segment function. (wowra2024generaltreatmentand pages 2-4)

10.3 Genetic testing (real-world implementation)

Gene panels (2023 snapshot)

Commercial panel testing for ASD shows substantial variability: * Across four ASD panels surveyed, FOXE3 was included in 100% (4/4) and PAX6 in 100% (4/4), but other common ASD genes (PITX2/FOXC1/CYP1B1/PITX3) were only present on ~50% of panels; PXDN was present on 75%. (procopio2023comparinggenepanels pages 2-4) * Panel scope varies widely; in a broader non-retinal panel survey, panels ranged from “1 to 893 genes” across indications, underscoring the need for careful selection and coverage review. (procopio2023comparinggenepanels pages 4-6) * Technical sensitivity varies by variant class; some labs report poor reliability for certain structural variants (e.g., CNVs <500 bp, larger indels), and variant interpretation differs among laboratories—supporting genetic counselor involvement. (procopio2023comparinggenepanels pages 6-7)

WES-based approaches (2024 cohort evidence)

A 2024 cohort study describing long-term molecular characterization of congenital ocular dysgenesis reports: * Use of WES in phenotype-overlapping congenital ocular disease and that, after filtering benign variants, “30.8% patients bore a pathogenic or likely pathogenic aberration in genes known to cause ocular dysgenesis.” (Journal of Human Genetics; Mar 2024; https://doi.org/10.1038/s10038-024-01237-6) (zucco2024abird’seye pages 3-4)

Single-gene testing

Historically, candidate-gene sequencing and positional approaches identified FOXE3 variants in families with congenital aphakia/ASD and informed inclusion of FOXE3 in diagnostic screening. (iseri2009seeingclearlythe pages 2-3)

10.4 Differential diagnosis

Genetically heterogeneous ASD disorders include variants in PAX6, PITX2, FOXC1, CYP1B1, PXDN, and others; phenotypic overlap is substantial, supporting broad-panel or exome approaches in many patients. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, procopio2023comparinggenepanels pages 1-2)

11. Outcome / prognosis

FOXE3-specific long-term prognosis depends on phenotype severity and treatability of complications (glaucoma, corneal opacity, aphakia/cataract, amblyopia).

Because many FOXE3 patients are clinically managed under broader entities (e.g., Peters anomaly), recent outcome statistics for those entities are informative: * In Peters anomaly, glaucoma is reported in 30–70% of patients; up to 60% may have systemic abnormalities/developmental delays, and PA is a common congenital indication for infant corneal transplantation. (wowra2024generaltreatmentand pages 1-2) * For penetrating keratoplasty in Peters anomaly, published outcomes vary widely (examples reported): graft survival/failure rates including 30% failure at 1 year, 70% failure at 5 years, and 77% failure at 10 years in some series; rejection is a major cause, and congenital/secondary glaucoma predicts graft failure. (wowra2024generaltreatmentand pages 7-8, wowra2024generaltreatmentand pages 4-7)

12. Treatment

There is no FOXE3 gene-specific therapy in clinical use; management is phenotype-driven and typically multidisciplinary.

12.1 Management of key ocular components (current practice)

Corneal opacity / Peters anomaly-type disease * Penetrating keratoplasty (PK) is first-line when corneal opacity prevents visual development; alternatives include optical sector iridectomy, pupil dilation, corneal rotation, and keratoprosthesis in selected cases. (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 8-10) * Postoperative priorities: maintain clear visual axis and prevent amblyopia; EUAs used to monitor grafts and IOP; immunosuppression regimens may include topical corticosteroids/cyclosporine A and sometimes systemic agents. (wowra2024generaltreatmentand pages 2-4, wowra2024generaltreatmentand pages 4-7)

Glaucoma / elevated IOP * Medical therapy and surgical options (e.g., cyclophotocoagulation) are used depending on anatomy/severity; an Oman case report of FOXE3-ASD2 documented treatment with anti-glaucoma medications and CPC. (alkhaldi2023homozygousvariantfoxe3 pages 1-3)

Aphakia / cataract * Optical correction (contact lenses/spectacles) and amblyopia therapy are key; in Peters anomaly care pathways, cataract removal and secondary IOL implantation are often deferred until ~2–3 years, with contact lenses for temporary aphakia. (wowra2024generaltreatmentand pages 4-7)

12.2 Suggested MAXO terms (examples)

(ontology suggestions; confirm during curation) * Corneal transplantation / penetrating keratoplasty * Antiglaucoma pharmacotherapy * Cyclophotocoagulation * Lensectomy / cataract extraction * Amblyopia therapy (occlusion therapy, atropine penalization) * Contact lens fitting for aphakia

13. Prevention

Primary prevention is not currently available for a monogenic congenital malformation; however: * Genetic counseling and cascade testing are central. * Reproductive options may include prenatal or preimplantation genetic testing once the familial FOXE3 variant(s) are known; panel-testing reviews explicitly note that prenatal/PGT discussion is outside scope but clinically relevant. (procopio2023comparinggenepanels pages 6-7)

14. Other species / natural disease

The retrieved human-focused evidence did not provide curated naturally occurring FOXE3-related ASD in non-human species; however, vertebrate developmental biology evidence supports conserved Foxe3 function in lens/anterior segment development (see model organisms below). (semina2001mutationsinthe pages 1-2)

15. Model organisms

The retrieved evidence base includes strong support from mouse developmental genetics: * The classic dysgenetic lens (dyl) mouse mutant has Foxe3 mutations and displays small eyes, corneal opacities, iris adhesions, persistent lens–cornea attachment, and cataracts, aligning with the concept that lens-primary defects drive secondary anterior segment malformations. (semina2001mutationsinthe pages 1-2)

Additional model-organism evidence (e.g., zebrafish foxe3 deficiency) was retrieved in searches but not fully incorporated into the evidence excerpts above; it should be added during extended curation if model details are required.

Key abstract-supported quotes (for knowledge base evidence items)

Reis et al. 2021 (Human Molecular Genetics; May 2021; https://doi.org/10.1093/hmg/ddab142): “Most families with recessive alleles… had severe corneal opacity (90%; sclerocornea in 47%), aphakia (83%) and microphthalmia (80%)…” (reis2021comprehensivephenotypicand pages 1-2)
Wowra et al. 2024 (J Clin Med; Jan 2024; https://doi.org/10.3390/jcm13020532): “Glaucoma is observed in 30–70% of patients…” and “Up to 60% of patients have systemic abnormalities or developmental delays…” (wowra2024generaltreatmentand pages 1-2)
Zucco et al. 2024 (J Hum Genet; Mar 2024; https://doi.org/10.1038/s10038-024-01237-6): “After ﬁltering benign and likely benign variants, 30.8% patients bore a pathogenic or likely pathogenic aberration in genes known to cause ocular dysgenesis.” (zucco2024abird’seye pages 3-4)

Embedded summary artifact

The following table consolidates inheritance patterns, variant classes, phenotype patterns, and key quantitative frequencies.

Inheritance mode	Typical phenotype pattern	Variant classes / inferred mechanism	Key quantitative phenotype data	Key citations
Autosomal recessive / biallelic FOXE3-related disease	Usually more severe congenital ocular malformations: dense corneal opacity, sclerocornea, primary aphakia, microphthalmia; frequent iris hypoplasia/aniridia and optic nerve anomalies; may include Peters-like anterior segment dysgenesis, cataract, and occasional extraocular findings	Typically truncating variants (nonsense, frameshift) throughout the single-exon gene and missense variants in the forkhead DNA-binding domain; overall most consistent with loss of function, though missense alleles show variable functional effects on protein stability, DNA binding, nuclear localization, and transcriptional activity	Reis 2021: corneal opacity 90%, sclerocornea 47%, aphakia 83%, microphthalmia 80%, aniridia/iris hypoplasia 89% (when assessed), optic nerve anomalies 60% (when assessed). Plaisancié 2018: recessive cases 84% of reported FOXE3 families; severe ocular phenotype in 77% of recessive cases; among patients with ≥1 truncating allele, 90% (37/41) had severe ocular disease; among biallelic missense cases, 69% (42/61) had severe ocular disease; ASD reported in 31% (19/61) of biallelic missense vs 17% (4/23) with two truncating variants (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)	(reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)
Autosomal dominant FOXE3-related disease	Typically milder and more variable anterior segment disease with congenital/early-onset cataract, Peters anomaly, iris abnormalities, microcornea, corneal scleralization, and occasional coloboma; most individuals have normal eye size, but overlap with recessive features can occur	Most often C-terminal extension / non-stop / elongating variants affecting or near the stop codon; dominant alleles show severe impairment in multiple functional assays and dominant-negative behavior in Reis 2021, while earlier genotype reviews also discuss possible gain-of-function effects for elongating alleles	Reis 2021: normal eye size 96%, cataract 99% in dominant pedigrees, with variable anterior segment anomalies. Plaisancié 2018: dominant cases 16% of reported FOXE3 families; severe ocular phenotype in 5% of dominant cases. Newfoundland pedigree: 11 affected among 31 examined relatives in a 4-generation family with a non-stop variant and variable ASD including Peters anomaly (reis2021comprehensivephenotypicand pages 1-2, doucette2011anovelnonstop pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)	(reis2021comprehensivephenotypicand pages 1-2, doucette2011anovelnonstop pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)
Genotype-phenotype overlap across AD and AR disease	Considerable overlap exists: cataract, anterior segment dysgenesis, Peters anomaly, aphakia, sclerocornea, and microphthalmia can occur in either inheritance class, although severity trends differ	Recessive missense alleles can be milder than recessive truncating alleles; dominant extension alleles usually milder but can occasionally produce features more typical of recessive disease	Reis 2021 identified overlap between dominant and recessive disease and noted that some recessive cases had isolated cataract, while some dominant individuals had microphthalmia, aphakia, or sclerocornea. Plaisancié 2018 concluded that mutation type, inheritance mode, and severity are correlated but not absolute (plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4, reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)	(plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4, reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

Table: This table summarizes the main genotype-phenotype patterns in FOXE3-related anterior segment dysgenesis, contrasting autosomal recessive/biallelic and autosomal dominant disease. It highlights the typical clinical presentations, variant classes and mechanisms, and the most useful quantitative phenotype frequencies from key studies.

Limitations and curation notes

MONDO/Orphanet/ICD/MeSH identifiers were not retrievable from the full texts accessed here and should be completed by direct database lookup during knowledge base normalization. (iseri2009seeingclearlythe pages 2-3)
Many treatment/outcome statistics come from Peters anomaly management literature (2024) rather than FOXE3-genotype-stratified cohorts; however, these are clinically relevant because Peters anomaly is a common manifestation within the FOXE3 spectrum. (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 7-8)
Variant-level details (HGVS for all known FOXE3 alleles, allele frequencies in gnomAD, ClinVar assertions) require direct ClinVar/gnomAD extraction; Reis et al. note FOXE3 alleles are rare/absent in gnomAD but full frequencies were not present in the excerpted evidence. (reis2021comprehensivephenotypicand pages 1-2)

References

(reis2021comprehensivephenotypicand pages 1-2): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.
(plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13): Julie Plaisancié, N. Ragge, H. Dollfus, J. Kaplan, D. Lehalle, C. Francannet, G. Morin, H. Colineaux, P. Calvas, and N. Chassaing. Foxe3 mutations: genotype‐phenotype correlations. Clinical Genetics, 93:837-845, Apr 2018. URL: https://doi.org/10.1111/cge.13177, doi:10.1111/cge.13177. This article has 42 citations and is from a peer-reviewed journal.
(iseri2009seeingclearlythe pages 2-3): Sibel Ugur Iseri, Robert J. Osborne, Martin Farrall, Alexander William Wyatt, Ghazala Mirza, Gudrun Nürnberg, Christian Kluck, Helen Herbert, Angela Martin, Muhammad Sajid Hussain, J. Richard O. Collin, Mark Lathrop, Peter Nürnberg, Jiannis Ragoussis, and Nicola K. Ragge. Seeing clearly: the dominant and recessive nature of foxe3 in eye developmental anomalies. Human Mutation, 30:1378-1386, Oct 2009. URL: https://doi.org/10.1002/humu.21079, doi:10.1002/humu.21079. This article has 109 citations and is from a domain leading peer-reviewed journal.
(wowra2024generaltreatmentand pages 1-2): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.
(procopio2023comparinggenepanels pages 1-2): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.
(zucco2024abird’seye pages 3-4): Jessica Zucco, Federica Baldan, Lorenzo Allegri, Elisa Bregant, Nadia Passon, Alessandra Franzoni, Angela Valentina D’Elia, Flavio Faletra, Giuseppe Damante, and Catia Mio. A bird’s eye view on the use of whole exome sequencing in rare congenital ophthalmic diseases. Journal of Human Genetics, 69:271-282, Mar 2024. URL: https://doi.org/10.1038/s10038-024-01237-6, doi:10.1038/s10038-024-01237-6. This article has 9 citations and is from a peer-reviewed journal.
(iseri2009seeingclearlythe pages 1-2): Sibel Ugur Iseri, Robert J. Osborne, Martin Farrall, Alexander William Wyatt, Ghazala Mirza, Gudrun Nürnberg, Christian Kluck, Helen Herbert, Angela Martin, Muhammad Sajid Hussain, J. Richard O. Collin, Mark Lathrop, Peter Nürnberg, Jiannis Ragoussis, and Nicola K. Ragge. Seeing clearly: the dominant and recessive nature of foxe3 in eye developmental anomalies. Human Mutation, 30:1378-1386, Oct 2009. URL: https://doi.org/10.1002/humu.21079, doi:10.1002/humu.21079. This article has 109 citations and is from a domain leading peer-reviewed journal.
(reis2021comprehensivephenotypicand pages 2-2): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.
(alkhaldi2023homozygousvariantfoxe3 pages 1-3): Zuha Alkhaldi, Moosa Allawati, and Nadia Alhashmi. Homozygous variant foxe3 causes autosomal recessive anterior segment dysgenesis type 2: a case report. Journal of Biochemical and Clinical Genetics, pages 75-79, Jan 2023. URL: https://doi.org/10.24911/jbcgenetics/183-1670866871, doi:10.24911/jbcgenetics/183-1670866871. This article has 0 citations.
(reis2021comprehensivephenotypicand pages 14-14): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.
(doucette2011anovelnonstop pages 1-2): Lance Doucette, Jane Green, Bridget Fernandez, Gordon J Johnson, Patrick Parfrey, and Terry-Lynn Young. A novel, non-stop mutation in foxe3 causes an autosomal dominant form of variable anterior segment dysgenesis including peters anomaly. European Journal of Human Genetics, 19:293-299, Mar 2011. URL: https://doi.org/10.1038/ejhg.2010.210, doi:10.1038/ejhg.2010.210. This article has 55 citations and is from a domain leading peer-reviewed journal.
(semina2001mutationsinthe pages 1-2): E. Semina, Isaac Brownell, H. Mintz‐Hittner, Jeffrey C. Murray, and M. Jamrich. Mutations in the human forkhead transcription factor foxe3 associated with anterior segment ocular dysgenesis and cataracts. Human molecular genetics, 10 3:231-6, Feb 2001. URL: https://doi.org/10.1093/hmg/10.3.231, doi:10.1093/hmg/10.3.231. This article has 239 citations and is from a domain leading peer-reviewed journal.
(reis2021comprehensivephenotypicand media 2b34c269): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.
(reis2021comprehensivephenotypicand media cd18957d): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.
(wowra2024generaltreatmentand pages 4-7): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.
(wowra2024generaltreatmentand pages 7-8): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.
(wowra2024generaltreatmentand pages 2-4): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.
(plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4): Julie Plaisancié, N. Ragge, H. Dollfus, J. Kaplan, D. Lehalle, C. Francannet, G. Morin, H. Colineaux, P. Calvas, and N. Chassaing. Foxe3 mutations: genotype‐phenotype correlations. Clinical Genetics, 93:837-845, Apr 2018. URL: https://doi.org/10.1111/cge.13177, doi:10.1111/cge.13177. This article has 42 citations and is from a peer-reviewed journal.
(procopio2023comparinggenepanels pages 2-4): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.
(procopio2023comparinggenepanels pages 4-6): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.
(procopio2023comparinggenepanels pages 6-7): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.
(wowra2024generaltreatmentand pages 8-10): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Source YAML

References & Deep Research

Deep Research

FOXE3-Related Anterior Segment Dysgenesis (ASD2; OMIM 610256): Comprehensive Research Report

Executive summary

1. Disease information

1.1 Definition / overview

1.2 Key identifiers

1.3 Common synonyms / alternative names

1.4 Evidence source type

2. Etiology

2.1 Primary causal factors

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes

3.1 Core phenotype spectrum and frequencies (human)

3.2 Phenotype characteristics (typical)

3.3 Suggested HPO terms (examples)

3.4 Quality of life impact

4. Genetic / molecular information

4.1 Causal gene

4.2 Pathogenic variant classes and functional consequences

4.3 Genotype–phenotype correlations (quantitative)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

6.1 Current mechanistic model (causal chain)

6.2 Suggested GO biological process terms (examples)

6.3 Suggested cell types (CL) and anatomical sites (UBERON)

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

9.1 Inheritance pattern

9.2 Epidemiology

10. Diagnostics

10.1 Clinical evaluation

10.2 Imaging and ancillary testing

10.3 Genetic testing (real-world implementation)

Gene panels (2023 snapshot)

WES-based approaches (2024 cohort evidence)

Single-gene testing

10.4 Differential diagnosis

11. Outcome / prognosis

12. Treatment

12.1 Management of key ocular components (current practice)

12.2 Suggested MAXO terms (examples)

13. Prevention

14. Other species / natural disease

15. Model organisms

Key abstract-supported quotes (for knowledge base evidence items)

Embedded summary artifact

Limitations and curation notes